LYTIX BIOPHARMA ASA

Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab

Oslo, Norway, 1 June 2026 - Lytix Biopharma ASA ("Lytix" or the "Company"), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that clinical data evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with ad...